Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 853

2.
3.

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.

Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G; AstraZeneca Arthroplasty Study Group..

Arch Intern Med. 2001 Oct 8;161(18):2215-21.

PMID:
11575978
4.
5.

Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial.

Navarro-Quilis A, Castellet E, Rocha E, Paz-Jiménez J, Planès A; Bemiparin Study Group in Knee Arthroplasty..

J Thromb Haemost. 2003 Mar;1(3):425-32.

6.

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.

Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M, Freij A; EXPRESS Study Group..

J Thromb Haemost. 2003 Dec;1(12):2490-6.

7.

Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).

Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N, Weber J; ECHOS Trial Group..

Int Angiol. 2006 Dec;25(4):335-42.

PMID:
17164738
8.

Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.

Fitzgerald RH Jr, Spiro TE, Trowbridge AA, Gardiner GA Jr, Whitsett TL, O'Connell MB, Ohar JA, Young TR; Enoxaparin Clinical Trial Group..

J Bone Joint Surg Am. 2001 Jun;83-A(6):900-6.

PMID:
11407799
9.

Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?

Strebel N, Prins M, Agnelli G, Büller HR.

Arch Intern Med. 2002 Jul 8;162(13):1451-6. Review.

PMID:
12090880
10.

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.

Haentjens P, De Groote K, Annemans L.

Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17. Epub 2004 Sep 10.

PMID:
15365714
11.

Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.

Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Espérance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F.

Ann Intern Med. 1996 Apr 1;124(7):619-26.

PMID:
8607589
12.
13.

Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.

Enyart JJ, Jones RJ.

Ann Pharmacother. 2005 Jun;39(6):1002-7. Epub 2005 May 10.

PMID:
15886295
14.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators..

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

15.

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M; OdiXa-Knee Study Group..

J Thromb Haemost. 2005 Nov;3(11):2479-86.

16.

A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.

Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT.

J Thromb Haemost. 2007 Apr;5(4):746-53.

17.

Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.

Samama CM, Vray M, Barré J, Fiessinger JN, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D; SACRE Study Investigators..

Arch Intern Med. 2002 Oct 28;162(19):2191-6.

PMID:
12390061
18.

A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).

Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD; EXPERT Study Group..

Thromb Haemost. 2009 Jan;101(1):68-76.

PMID:
19132191
19.

Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.

Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW.

J Thromb Haemost. 2003 Oct;1(10):2119-30.

20.

[Venous thromboembolism prophylaxis after total hip arthroplasty].

Kučera T, Malý R, Urban K, Sponer P.

Acta Chir Orthop Traumatol Cech. 2011;78(2):101-5. Czech.

PMID:
21575551

Supplemental Content

Support Center